加载中
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
收盘时
US$14.30
−US$0.42 · -2.85%
盘后
US$14.30
US$0.00 · 0.00%
10月13日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
日内区间
当前US$14.30
52周区间
当前US$14.30
盘中时间采用ET。市场数据可能有所延迟。
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
日内区间
当前US$14.30
52周区间
当前US$14.30
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$26.00
上涨空间 81.82%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6173.52万0.00%2.3万亿 USD0.03%US$381.32-0.07%
Vanguard Morningstar Small-Cap ETFVB4464.81万0.02%1853亿 USD0.03%US$288.160.00%
iShares Russell 2000 ETFIWM4027.19万0.05%787.4亿 USD0.19%US$276.71-0.43%
Vanguard Morningstar Small-Cap Growth ETFVBK2557.89万0.06%447亿 USD0.05%US$338.78-0.62%
Vanguard Extended Market ETFVXF2158.62万0.02%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Growth ETFIWO1352.25万0.10%139.17亿 USD0.24%US$351.1-0.74%
iShares Biotechnology ETFIBB1200.98万0.11%108.2亿 USD0.44%US$200.02-2.08%
Vanguard Russell 2000 ETFVTWO1085.12万0.06%180亿 USD0.06%US$111.77-0.45%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
